TY  - GEN 
AU  - Naranjo Muñoz, Javier
AU  - Borrego, Francisco
AU  - Rocha, José Luis
AU  - Salgueira Lazo, Mercedes
AU  - Martín-Gomez, Maria Adoración
AU  - Orellana, Cristhian
AU  - Morales, Ana
AU  - Vallejo, Fernando
AU  - Hidalgo, Pilar
AU  - Rodríguez, Francisca
AU  - Garófano, Remedios
AU  - González, Isabel
AU  - Esteban, Rafael
AU  - Espinosa, Mario
AU  - Andalusian Group of ADPKD and Hereditary Kidney Diseases
A4  - Medicina
PY  - 2022
SN  - 2296-858X
UR  - http://hdl.handle.net/10498/29558
AB  - Background: Tolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of...
LA  - eng
PB  - FRONTIERS MEDIA SA
KW  - glomerular filtration rate (eGFR)
KW  - hepatic toxicity
KW  - polycystic kidney disease (PKD)
KW  - tolvaptan
KW  - urinary osmolality
TI  - Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
DO  - 10.3389/fmed.2022.987092
ER  -